홈 › 만성 림프구성 백혈병 › 미시간

미시간의 만성 림프구성 백혈병 임상 시험

만성 림프구성 백혈병 관련 연구 12개가 미시간 내 여러 지역에서 참여자를 모집하고 있습니다.

미시간의 도시

공식 연구 텍스트(영어)

Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL

Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
Trinity Health IHA Medical Group Hematology Oncology - Canton, Canton
Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital, Chelsea
외 4개

피험자 모집 중3상

65세 이상 · 모든 성별 · 2026. 10. 2. 업데이트됨 · NCT07321652

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

MyMichigan Medical Center Gratiot, Alma
MyMichigan Medical Center Alpena, Alpena
Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
외 68개

피험자 모집 중관찰 연구건강한 지원자 환영

40세 ~ 75세 · 모든 성별 · 2026. 10. 2. 업데이트됨 · NCT05334069

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
Bronson Battle Creek, Battle Creek
Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
외 43개

피험자 모집 중3상

18세 이상 · 모든 성별 · 2026. 9. 30. 업데이트됨 · NCT04269902

A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

The Cancer and Hematology Centers, Grand Rapids

피험자 모집 중3상

18세 이상 · 모든 성별 · 2026. 9. 28. 업데이트됨 · NCT06943872

A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

Karmanos Cancer Institute, Detroit

피험자 모집 중1/2상

18세 이상 · 모든 성별 · 2026. 9. 28. 업데이트됨 · NCT05006716

A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

Corewell Health the Michigan Cancer Consortium, Grand Rapids

피험자 모집 중3상

18세 이상 · 모든 성별 · 2026. 9. 28. 업데이트됨 · NCT06846671

A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Karmanos Cancer Institute, Detroit

피험자 모집 중3상

18세 이상 · 모든 성별 · 2026. 9. 28. 업데이트됨 · NCT06973187

A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

Corewell Health-Lemmon Holton Cancer Pavilion ( Site 0011), Grand Rapids

피험자 모집 중3상

18세 이상 · 모든 성별 · 2026. 9. 24. 업데이트됨 · NCT06136559

A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

Karmanos Cancer Center, Detroit

피험자 모집 중2상

18세 이상 · 모든 성별 · 2026. 9. 17. 업데이트됨 · NCT07221500

Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome

West Michigan Cancer Center, Kalamazoo

피험자 모집 중관찰 연구

18세 이상 · 모든 성별 · 2026. 5. 7. 업데이트됨 · NCT02269592

A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Henry Ford Hospital /ID# 270973, Detroit

피험자 모집 중3상

18세 이상 · 모든 성별 · 2026. 4. 9. 업데이트됨 · NCT06428019

HPC Offered for PRESERVE Expansion

Henry Ford Health, Detroit

피험자 모집 중관찰 연구

12세 ~ 80세 · 모든 성별 · 2025. 8. 28. 업데이트됨 · NCT07145411

ClinicalTrials.gov 출처, 2026. 10. 5. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.